HER2 ASCO guidelines. the answer to everything?;HER2-ASCO-Guidelines Der Weisheit letzter Schluss?

Pathologe

Volumn 31, Issue SUPPL. 2, 2010, Pages 285-291

  Burandt, E ^a   Sauter, G ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

ASCO CAP; Fluorescence in situ hybridization; HER2; Immunohistochemistry; Methodical issues

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORMALDEHYDE; HER2 PROTEIN, HUMAN; LAPATINIB; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE; TRASTUZUMAB; TUMOR MARKER;

ARTICLE; BREAST TUMOR; DRUG DELIVERY SYSTEM; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETICS; HUMAN; PATHOLOGY; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROGNOSIS; TISSUE FIXATION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; FORMALDEHYDE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; QUINAZOLINES; RECEPTOR, ERBB-2; TISSUE FIXATION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79953177055     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-010-1348-4     Document Type: Article

References (23)

1. Al-Kuraya K, Schraml P, Sheikh S et al (2005) Predominance of high-grade pathway in breast cancer development of Middle East women. Mod Pathol 18:891-897
2. Baselga J, Tripathy D, Mendelsohn J et al (1999) Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 26:78-83
3. Clark GM, Mcguire WL (1991) Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51:944-948
4. Dowsett M, Cooke T, Ellis I et al (2000) Assessment of HER2 status in breast cancer: why, when and how? Eur J Cancer 36:170-176
5. Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312
6. Kallioniemi OP, Kallioniemi A, Kurisu W et al (1992) ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A 89:5321-5325
7. Marchio C, Lambros MB, Gugliotta P et al (2009) Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 219:16-24
8. Mccann AH, Dervan PA, O'regan M et al (1991) Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 51:3296-3303
9. Pauletti G, Godolphin W, Press MF et al (1996) Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13:63-72
10. Penault-Llorca F, Adelaide J, Houvenaeghel G et al (1994) Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol 173:65-75
11. Roche PC, Ingle JN (1999) Increased HER2 with U.S. Food and Drug Administration-approved antibody. J Clin Oncol 17:434
12. Sauter G, Lee J, Bartlett JM et al (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27:1323-1333
13. Simon R, Nocito A, Hubscher T et al (2001) Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 93:1141-1146
14. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182
15. Stefano R, Agostara B, Calabro M et al (2004) Expression levels and clinical-pathological correlations of HER2/neu in primary and metastatic human breast cancer. Ann N Y Acad Sci 1028:463-472
16. Tapia C, Schraml P, Simon R et al (2004) HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies. Int J Oncol 25:1551-1557
17. Todorovic-Rakovic N, Jovanovic D, Neskovic-Konstantinovic Z et al (2007) Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer. Exp Mol Pathol 82:262-268
18. Toikkanen S, Helin H, Isola J et al (1992) Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 10:1044-1048
19. Tripathy D, Slamon DJ, Cobleigh M et al (2004) Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 22:1063-1070
20. Tuma RS (2005) Trastuzumab trials steal show at ASCO meeting. J Natl Cancer Inst 97:870-871
21. Van De Vijver M (2002) Emerging technologies for HER2 testing. Oncology 63 (Suppl 1):33-38
22. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18-43
23. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145